<DOC>
	<DOC>NCT02945657</DOC>
	<brief_summary>The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.</brief_summary>
	<brief_title>Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>This is a multi-center, open-label study to assess the degree of systemic exposure and safety of MM36 1% ointment following 4 weeks of twice daily dosing under maximal-use conditions in pediatric subjects with atopic dermatitis.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Subjects 2 to &lt;18 years of age Diagnosis of atopic dermatitis (AD) AD affecting ≥ 35% BSA if 2 to &lt; 12 years of age or ≥ 25% if subject is ≥ 12 years of age (excluding scalp and venous access areas) Active or acute viral skin infection History of recurrent bacterial infection Malignancy Clinically significant history or physical findings that may pose a health risk to subject or may have an impact on study assessments</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>